Physician profile
Beth A Bash
NPI 1225079973
$6,766.89
in general payments reported to CMS, 2019-2025
35 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,195 · 2022: $1,173 · 2023: $1,219 · 2024: $1,736 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,345 · Long Term Medical Supply Or Device Loan: $29.97 · Education: $24.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.14 |
| Long Term Medical Supply Or Device Loan | $29.97 |
| Education | $24.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,235.90 | 2021-2025 | Trelegy Ellipta, Rotarix, Bexsero |
| Novo Nordisk INC | $857.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $846.35 | 2021-2025 | |
| Lilly USA, LLC | $646.04 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $521.37 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $432.40 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.05 | 2021-2025 | Ofev, Jascayd, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.37 | 2021-2024 | Xifaxan, Trulance |
| Amgen INC. | $192.37 | 2023-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $170.04 | 2021-2025 | Ajovy |
| Abbott Laboratories | $121.61 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Currax Pharmaceuticals LLC | $116.27 | 2021-2023 | Onzetra Xsail, Contrave |
| Amarin Pharma, INC. | $112.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $111.88 | 2021-2023 | Belsomra |
| Exact Sciences Corporation | $106.84 | 2023-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $101.74 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $77.18 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $73.51 | 2021-2025 | Seglentis, Livalo, Zoryve |
| Astellas Pharma US INC | $69.32 | 2022-2024 | Veozah, Myrbetriq |
| Grifols USA, LLC | $64.13 | 2021 | |
| Sanofi-Aventis U.S. LLC | $64.09 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.44 | 2021-2022 | |
| Daiichi Sankyo INC. | $53.41 | 2021-2022 | |
| Biogen, INC. | $49.84 | 2021-2022 | |
| Stryker Corporation | $34.01 | 2025 | Flowtriever |
| Dexcom, INC. | $33.05 | 2022 | |
| Almatica Pharma LLC | $31.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.29 | 2021 | |
| Sanofi Pasteur INC. | $29.24 | 2023-2024 | |
| Heartflow, INC. | $23.45 | 2024 | |
| Edwards Lifesciences Corporation | $20.84 | 2023 | |
| Impel Pharmaceuticals INC. | $17.17 | 2023 | Trudhesa |
| Viatris Specialty LLC | $14.86 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $14.36 | 2021 | |
| Eisai INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Bash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.